Literature DB >> 8942969

Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.

A I Levey1.   

Abstract

Cholinergic transmission at muscarinic acetylcholine receptors (mAChR) has been implicated in higher brain functions such as learning and memory, and loss of synapses may contribute to the symptoms of Alzheimer disease. A heterogeneous family of five genetically distinct mAChR subtypes differentially modulate a variety of intracellular signaling systems as well as the processing of key molecules involved in the pathology of the disease. Although many muscarinic effects have been identified in memory circuits, including a diversity of pre- and post-synaptic actions in hippocampus, the identities of the molecular subtypes responsible for any given function remain elusive. All five mAChR genes are expressed in hippocampus, and subtype-specific antibodies have enabled identification, quantification, and localization of the encoded proteins. The m1, m2, and m4 mAChR proteins are most abundant in forebrain regions and they have distinct cellular and subcellular localizations suggestive of various pre- and postsynaptic functions in cholinergic circuits. The subtypes are also differentially altered in postmortem brain samples from Alzheimer disease cases. Further understanding of the molecular pharmacology of failing synapses in Alzheimer disease, together with the development of new subtype-selective drugs, may provide more specific and effective treatments for the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8942969      PMCID: PMC33643          DOI: 10.1073/pnas.93.24.13541

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  63 in total

Review 1.  Muscarinic receptor subtypes.

Authors:  E C Hulme; N J Birdsall; N J Buckley
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

2.  Human memory and the cholinergic system. A relationship to aging?

Authors:  D A Drachman; J Leavitt
Journal:  Arch Neurol       Date:  1974-02

3.  Localization of a family of muscarinic receptor mRNAs in rat brain.

Authors:  N J Buckley; T I Bonner; M R Brann
Journal:  J Neurosci       Date:  1988-12       Impact factor: 6.167

4.  Binding sites for [3H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices.

Authors:  P A Lapchak; D M Araujo; R Quirion; B Collier
Journal:  Brain Res       Date:  1989-09-04       Impact factor: 3.252

5.  Interaction acetylcholine-glutamate in rat hippocampus: involvement of two subtypes of M-2 muscarinic receptors.

Authors:  M Marchi; M Raiteri
Journal:  J Pharmacol Exp Ther       Date:  1989-03       Impact factor: 4.030

Review 6.  The cholinergic hypothesis of geriatric memory dysfunction.

Authors:  R T Bartus; R L Dean; B Beer; A S Lippa
Journal:  Science       Date:  1982-07-30       Impact factor: 47.728

7.  Carbachol depresses synaptic responses in the medial but not the lateral perforant path.

Authors:  J S Kahle; C W Cotman
Journal:  Brain Res       Date:  1989-03-13       Impact factor: 3.252

8.  Sensory modulation of hippocampal transmission. II. Evidence for a cholinergic locus of inhibition in the Schaffer-CA1 synapse.

Authors:  O Herreras; J M Solís; A S Herranz; R Martín del Río; J Lerma
Journal:  Brain Res       Date:  1988-10-04       Impact factor: 3.252

9.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

Authors:  E K Perry; B E Tomlinson; G Blessed; K Bergmann; P H Gibson; R H Perry
Journal:  Br Med J       Date:  1978-11-25

10.  Essential role of neocortical acetylcholine in spatial memory.

Authors:  J Winkler; S T Suhr; F H Gage; L J Thal; L J Fisher
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

View more
  87 in total

1.  The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.

Authors:  C Weiss; A R Preston; M M Oh; R D Schwarz; D Welty; J F Disterhoft
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

2.  The utility of muscarinic agonists in the treatment of Alzheimer's disease.

Authors:  William S Messer
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

3.  Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators.

Authors:  Karen A Selz; Arnold J Mandell; Michael F Shlesinger; Vani Arcuragi; Michael J Owens
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

Review 4.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 5.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

Review 6.  The keystone of Alzheimer pathogenesis might be sought in Aβ physiology.

Authors:  D Puzzo; W Gulisano; O Arancio; A Palmeri
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 7.  Transmitter receptors and functional anatomy of the cerebral cortex.

Authors:  Karl Zilles; Nicola Palomero-Gallagher; Axel Schleicher
Journal:  J Anat       Date:  2004-12       Impact factor: 2.610

8.  Gene-based analysis suggests association of the nicotinic acetylcholine receptor beta1 subunit (CHRNB1) and M1 muscarinic acetylcholine receptor (CHRM1) with vulnerability for nicotine dependence.

Authors:  Xiang-Yang Lou; Jennie Z Ma; Thomas J Payne; Joke Beuten; Karen M Crew; Ming D Li
Journal:  Hum Genet       Date:  2006-07-28       Impact factor: 4.132

9.  Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.

Authors:  Chelsea T Tiernan; Stephen D Ginsberg; Bin He; Sarah M Ward; Angela L Guillozet-Bongaarts; Nicholas M Kanaan; Elliott J Mufson; Scott E Counts
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

10.  A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

Authors:  Jerri M Rook; Jeanette L Bertron; Hyekyung P Cho; Pedro M Garcia-Barrantes; Sean P Moran; James T Maksymetz; Kellie D Nance; Jonathan W Dickerson; Daniel H Remke; Sichen Chang; Joel M Harp; Anna L Blobaum; Colleen M Niswender; Carrie K Jones; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2018-05-08       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.